Arcturus Therapeutics Holdings Inc. ARCT
At closeNov 4, 2026, 4:01 PM EST
After hours · Nov 4, 4:01 PM ET
- YTD
- +77.32%
- 1 year
- +21.72%
- Market cap
- 308.96M
- Revenue (ttm)
- 160.40M
- Profit margin
- -39.05%
- EPS (ttm)
- -3.33
- Shares out
- 27.09M
- Forward P/E
- -7.41
- YTD return
- +77.32%
- 1-year return
- +21.72%
- Volume
- 495.76K
- Avg volume
- 1.00M
- Open
- 9.89
- Previous close
- 9.54
- Day's range
- 9.82 – 10.88
- 52-week range
- 5.53 – 16.93
- Beta
- 2.64
- Analysts
- Strong Buy
- Price target
- 79.47 (+631.1%)
2Y -7.48 (-40.76%)
Key statistics
- Enterprise value
- 211.56M
- PEG ratio
- 0.00
- Price / sales
- 2.79
- Price / book
- 1.71
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -7.70%
- Free cash flow
- -40.26M
- Total cash
- 237.18M
- Total debt
- 29.42M
- Return on equity
- -23.12%
- Short % of float
- 25.29%
- 50-day average
- 18.22
- 200-day average
- 24.44
Analyst view
Consensus: strong buy
- Target (low)
- 44.00
- Target (mean)
- 79.47
- Target (high)
- 140.00
- Strong buy3
- Buy7
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.22333.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.70 | -0.26 | +0.44 | +62.86% |
| Aug 5, 2024 | Jun 1, 2024 | -1.85 | -0.64 | +1.21 | +65.41% |
| May 8, 2024 | Mar 1, 2024 | -1.17 | -1.00 | +0.17 | +14.53% |
| Mar 7, 2024 | Dec 1, 2023 | -1.69 | -0.32 | +1.37 | +81.07% |
| Nov 14, 2023 | Sep 1, 2023 | -1.79 | -0.61 | +1.18 | +65.92% |
| Aug 7, 2023 | Jun 1, 2023 | 0.09 | -1.98 | -2.07 | -2,300.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 17, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Dec 16, 2024 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Nov 8, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 12, 2024 | Leerink Partners | init | — | Outperform |
| Aug 8, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 6, 2024 | Cantor Fitzgerald | reit | — | Overweight |
About Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- arcturusrx.com
News
Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 5, 2026 
Transcript: Arcturus Therapeutics Q2 2026 Earnings Conference Call 
Humana, Evolution Metals & Technologies, Fastly And Other Big Stocks Moving Higher On Friday 
CrowdStrike To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Friday 
Leerink Partners Maintains Outperform on Arcturus Therapeutics, Raises Price Target to $19 
4 RNA Therapeutics Stocks Leading the Next Wave of Innovation 
Arcturus Highlights ARCT-810 Phase II Data, Unveils Next-Gen OTC Therapy Platform 
Why Is Arcturus Therapeutics Stock Gaining Thursday? 
Citigroup Upgrades Arcturus Therapeutics to Buy, Raises Price Target to $20 
Everpure, Fervo Energy, Charles River Laboratories And Other Big Stocks Moving Higher On Thursday
Your note
Sign in to keep a note on ARCT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARLOW JAMES F. | Director | Conversion of Exercise of derivative security | Jun 13, 2024 | 13,131 |
| CHIVUKULA PADMANABH | Chief Operating Officer | Sale | Oct 14, 2024 | 435,334 |
| FARRELL PETER CRAIG | Director | Conversion of Exercise of derivative security | Jun 13, 2024 | 98,696 |
| HOLMES EDWARD W. | Director | Conversion of Exercise of derivative security | Jun 13, 2024 | 3,131 |
| KUMMERFELD KEITH C | Officer | Sale | Jul 13, 2023 | 950 |
| MARANTZ JING L. | Director | Conversion of Exercise of derivative security | Jun 13, 2024 | 3,131 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Federated Hermes, Inc. | 17.33% | 4,694,060 | 77.59M | Sep 29, 2024 |
| Blackrock Inc. | 10.90% | 2,952,013 | 48.80M | Sep 29, 2024 |
| Nikko Asset Management Americas, Inc. | 8.55% | 2,315,294 | 38.27M | Sep 29, 2024 |
| Sumitomo Mitsui Trust Holdings, Inc. | 8.40% | 2,275,715 | 37.62M | Sep 29, 2024 |
| ARK Investment Management, LLC | 7.76% | 2,101,038 | 34.73M | Sep 29, 2024 |
| Vanguard Group Inc | 5.82% | 1,576,926 | 26.07M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Federated Hermes Kaufmann Fund | 8.99% | 2,435,880 | 40.27M | Jul 30, 2024 |
| Federated Hermes Kaufmann Small Cap Fund | 8.11% | 2,198,020 | 36.33M | Jul 30, 2024 |
| ARK ETF Tr-ARK Genomic Revolution ETF | 7.53% | 2,038,675 | 33.70M | Oct 30, 2024 |
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 2.77% | 749,644 | 12.39M | Sep 29, 2024 |
| Vanguard Total Stock Market Index Fund | 2.67% | 723,640 | 11.96M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.19% | 593,781 | 9.82M | Oct 30, 2024 |